• 4. April 2025

InDex Pharmaceuticals receives approval of the International Nonproprietary Name (INN) cobitolimod for their lead drug candidate Kappaproct®

ByInDex Pharmaceuticals

Feb. 10, 2016

Teile den Beitrag mit Freunden